1,645 results match your criteria Clinical Lung Cancer[Journal]


Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.

Clin Lung Cancer 2019 Mar 29. Epub 2019 Mar 29.

Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Seoul National University Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Introduction: Leptomeningeal metastasis (LM), still an area of unmet need, has frequently been observed in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Because the antitumor efficacy of systemic cytotoxic agents against LM is unclear, we explored the role of pemetrexed in the treatment of patients with LM from EGFR-mutant NSCLC.

Patients And Methods: We retrospectively reviewed the medical records of patients with LM from EGFR-mutant NSCLC treated between 2006 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.03.005DOI Listing

Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.

Clin Lung Cancer 2019 Mar 25. Epub 2019 Mar 25.

Internal Medicine III, Wakayama Medical University, Wakayama, Japan.

Background: Blockade of the programmed death receptor-1 (PD-1) pathway is effective against solid tumors including lung cancer. PD-ligand 1 (PD-L1) expression on tumor tissue serves as a predictive biomarker for the efficacy of PD-1 pathway blockade. Here, we evaluated the expression of PD-L1 on circulating tumor cells (CTCs) in patients with lung cancer. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304193007
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2019.03.004DOI Listing
March 2019
1 Read

Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.

Clin Lung Cancer 2019 Mar 26. Epub 2019 Mar 26.

Department of Radiation Oncology, New York Proton Center, New York, NY. Electronic address:

Background: Management options for unresected malignant pleural mesothelioma (MPM) are largely limited to palliative chemotherapy and best supportive care. This study sought to delineate subgroups most likely to benefit from chemotherapy.

Patients And Methods: The National Cancer Database was queried for newly-diagnosed unresected sarcomatoid, biphasic, and/or metastatic (M1) MPM. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304193007
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2019.03.003DOI Listing
March 2019
3 Reads

Thoracic Oncology Multidisciplinary Clinic Reduces Unnecessary Health Care Expenditure Used in the Workup of Patients With Non-small-cell Lung Cancer.

Clin Lung Cancer 2019 Mar 12. Epub 2019 Mar 12.

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD.

Background: National costs of lung cancer care exceed $12 billion. We investigate the resource-savings benefit of a single-day thoracic oncology multidisciplinary clinic (MDC) in the diagnostic period prior to non-small-cell lung cancer (NSCLC) treatment.

Materials And Methods: From July 2007 to January 2015, patients with NSCLC treated with multimodality therapy at a tertiary hospital-based cancer center in Maryland were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.010DOI Listing

Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.

Clin Lung Cancer 2019 Feb 27. Epub 2019 Feb 27.

Department of Oncology, the Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.014DOI Listing
February 2019
3 Reads

Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases.

Clin Lung Cancer 2019 Feb 26. Epub 2019 Feb 26.

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:

Background: As the first-line treatment, afatinib is commonly used in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, dose adjustments are frequently required. The optimal dose of afatinib for brain metastasis has seldom been investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.009DOI Listing
February 2019
2 Reads

Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.

Clin Lung Cancer 2019 Mar 4. Epub 2019 Mar 4.

Department of Medical Oncology, Hospital Clínic, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.022DOI Listing

Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.

Clin Lung Cancer 2019 Mar 4. Epub 2019 Mar 4.

Division of Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan.

Introduction: This study was aimed at clarifying the failure pattern after definitive chemoradiotherapy in patients with stage III non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and/or anaplastic lymphoma kinase (ALK) translocation.

Methods And Materials: This retrospective study was a single-institution study conducted on patients with unresectable stage III non-squamous NSCLC treated by definitive chemoradiotherapy between January 2006 and March 2016. Only patients with information of EGFR mutations and/or ALK translocation were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.021DOI Listing
March 2019
1 Read

Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray.

Clin Lung Cancer 2019 Feb 27. Epub 2019 Feb 27.

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Electronic address:

Background: The immunohistochemical analysis of programmed cell death ligand 1 (PD-L1) expression in tumor tissue of non-small-cell lung cancer patients has now been integrated in the diagnostic workup. Analysis is commonly done on small tissue biopsy samples representing a minimal fraction of the whole tumor. The aim of the study was to evaluate the correlation of PD-L1 expression on biopsy specimens with corresponding resection specimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.012DOI Listing
February 2019
1 Read
3.104 Impact Factor

A Prospective, Randomized Trial for the Comparison of 19-G and 22-G Endobronchial Ultrasound-Guided Transbronchial Aspiration Needles; Introducing a Novel End Point of Sample Weight Corrected for Blood Content.

Clin Lung Cancer 2019 Mar 4. Epub 2019 Mar 4.

Department of Interventional Pneumology, University Medicine Essen - Ruhrlandklinik, Essen, Germany; The Arthur G. James Thoracic Cancer Center, The Ohio State University, Columbus, OH. Electronic address:

Background: The use of 22- or 21-gauge (G) endobronchial ultrasound (EBUS) needles are recommended for lung cancer diagnosis and staging. Performance of detailed molecular workup and programmed death ligand 1 (PD-L1) staining in lung cancer patients increases the demand for tissue. The aim of this prospective, randomized two-center trial was to compare 19-G and 22-G EBUS needles regarding tissue quality, diagnostic yield, feasibility, safety, performance, and blood content. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.019DOI Listing
March 2019
3.104 Impact Factor

A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib.

Clin Lung Cancer 2019 Mar 4. Epub 2019 Mar 4.

Department of Respiratory Medicine, Jinling Hospital, Nanjing, Jiangsu, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.020DOI Listing

Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients.

Clin Lung Cancer 2019 Mar 4. Epub 2019 Mar 4.

Department of Radiation Oncology, University of Rochester, Rochester, NY.

Introduction: Retrospective studies have shown an increased risk of second primary lung cancer in patients with a history of head and neck cancer (HNC). No population-based study has examined the overall survival (OS) outcomes of patients with second primary non-small-cell lung cancer (NSCLC) after HNC comparison with patients with first primary NSCLC.

Patients And Methods: Individuals with histologically confirmed NSCLC diagnosed after nonmetastatic squamous-cell carcinoma of the head and neck (HNC-NSCLC; n = 3597) were identified in Surveillance, Epidemiology, and End Results 18 registries (1988-2013). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.017DOI Listing
March 2019
1 Read

Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.

Clin Lung Cancer 2019 Mar 1. Epub 2019 Mar 1.

Mayo Clinic Cancer Center, Rochester, MN. Electronic address:

Neuroendocrine neoplasms (NEN) are a family of malignancies of diverse origin, including the lung, gastrointestinal tract, and pancreas. Lung NEN include well differentiated neuroendocrine tumors (NET) classified as typical carcinoids or atypical carcinoids, and poorly differentiated neuroendocrine carcinomas classified as small-cell lung carcinoma or large-cell neuroendocrine carcinoma. According to a recent analysis of a large, population-based registry, approximately one-third of all patients with lung typical/atypical carcinoids have distant metastases at diagnosis, and median survival for these patients is 24 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.007DOI Listing
March 2019
2 Reads

Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.

Clin Lung Cancer 2019 Feb 27. Epub 2019 Feb 27.

Medical Oncology, Thoracic Oncology Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.

Introduction: Treatment with immune checkpoint inhibitors beyond progression is associated with improved survival in patients with melanoma and clear-cell renal carcinoma. Whether this association exists for patients with non-small-cell lung cancer (NSCLC) is currently still unclear.

Patients And Methods: We performed a multi-institutional retrospective study based on landmark and multivariable analyses to evaluate the safety and efficacy of treatment with nivolumab beyond Response Evaluation Criteria In Solid Tumors (RECIST) v1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.001DOI Listing
February 2019
1 Read

Patterns of Care and Survival in Stage III NSCLC Among Black and Latino Patients Compared With White Patients.

Clin Lung Cancer 2019 Feb 28. Epub 2019 Feb 28.

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD. Electronic address:

Background: Race and socioeconomic status have continued to affect the survival and patterns of care of patients with non-small-cell lung cancer (NSCLC). However, data evaluating these associations in patients with stage III disease remain limited. Therefore, we investigated the patterns of care and overall survival (OS) of black and Latino patients with locally advanced NSCLC compared with white patients, using the National Cancer Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.015DOI Listing
February 2019
1 Read
3.104 Impact Factor

Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).

Clin Lung Cancer 2019 Feb 27. Epub 2019 Feb 27.

Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Progression-free survival (PFS) of patients with non-small-cell lung cancer with pleural or pericardial effusion is expected to be prolonged with combination use of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor plus bevacizumab compared with that with an EGFR-tyrosine kinase inhibitor alone. Phase I clinical trial data have been reported for combined treatment with osimertinib plus bevacizumab and demonstrated their safety, but the efficacy remains unclear, particularly in patients with pleural or pericardial effusion. This is an ongoing single arm, prospective, open-label, multicenter, phase II trial to evaluate the efficacy and safety of osimertinib plus bevacizumab combination therapy in EGFR mutation-positive patients with untreated or recurrent non-small-cell lung cancer and pleural and/or pericardial effusion. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304193006
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2019.02.016DOI Listing
February 2019
3 Reads

EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib.

Clin Lung Cancer 2019 Feb 26. Epub 2019 Feb 26.

Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.

Background: Patients with advanced-stage non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations are successfully treated with tyrosine kinase inhibitors (TKIs). However, treatment outcome varies significantly. Previously, we found the polymorphism 181946C>T (rs2293347) located in exon 25 of the EGFR gene to be a predictor of improved outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.011DOI Listing
February 2019

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.

Clin Lung Cancer 2019 Feb 26. Epub 2019 Feb 26.

Pathology Department, Hospital del Mar, Barcelona, Spain; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain. Electronic address:

Background: Detection of ALK and ROS1 gene rearrangements in non-small-cell lung cancer is required for directing patient care. Although fluorescence in situ hybridization (FISH) and immunohistochemistry have been established as gold standard methods, next-generation sequencing (NGS) platforms are called to be at least equally successful. Comparison of these methods for translation into daily use is currently under investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.008DOI Listing
February 2019
1 Read

Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2019 Feb 21. Epub 2019 Feb 21.

Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona, Spain; Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:

Introduction: Epidermal growth factor receptor (EGFR) pathway deregulation promotes the acquisition of stemlike properties in non-small-cell lung cancer. EGFR inhibition through NOTCH enriches lung cancer stem cells (CSCs). Src through Yes-associated protein 1 (YAP1) activates NOTCH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.005DOI Listing
February 2019
2 Reads

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

Clin Lung Cancer 2019 Feb 21. Epub 2019 Feb 21.

Medical Oncology, University Hospital of Parma, Parma, Italy.

Background: Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non-small-cell lung cancer (NSCLC).

Methods: Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Univariate and multivariate analyses were performed to evaluate the relationships between types of irAEs (differentiated according to system/organ involved and to single-site/multiple-site), overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.006DOI Listing
February 2019
3 Reads
3.104 Impact Factor

Palliative Care Referrals for Advanced Non-small-cell Lung Cancer (NSCLC): Patient and Provider Attitudes and Practices.

Clin Lung Cancer 2019 Feb 20. Epub 2019 Feb 20.

Vanderbilt University Medical Center, Nashville, TN.

Background: Early palliative care (PC) improves quality of life and prolongs survival for patients with metastatic non-small cell lung cancer (NSCLC). Despite these benefits, patient- and provider-specific barriers lead to underutilization of PC. To investigate these barriers, this 2 part study surveyed United States oncologists and patients with NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.002DOI Listing
February 2019
1 Read

Inoperable Pulmonary Carcinoid Tumors: Local Control Rates With Stereotactic Body Radiotherapy/Hypofractionated RT With Image-Guided Radiotherapy.

Clin Lung Cancer 2019 Feb 14. Epub 2019 Feb 14.

Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY.

Introduction: Surgery is the standard of care for pulmonary carcinoid tumors; however, options for inoperable patients are few. We report the outcomes of inoperable pulmonary carcinoid patients treated with stereotactic body radiotherapy (SBRT).

Patients And Methods: From an institutional database, we retrospectively identified patients treated with SBRT for pulmonary carcinoid tumors from 2007 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.003DOI Listing
February 2019
1 Read

Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma.

Clin Lung Cancer 2019 Jan 26. Epub 2019 Jan 26.

Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, South Korea. Electronic address:

Background: Lung cancer is one of the most lethal malignancies, with a 5-year survival rate < 20% in patients with stage IV lung cancer. Impaired host immunity is associated with lung cancer pathogenesis, and interferon gamma (IFN-γ) plays an important role in antitumor immune surveillance. We evaluated the clinical significance of ex vivo production of IFN-γ in patients with lung adenocarcinoma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304193000
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2019.01.002DOI Listing
January 2019
6 Reads

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

Clin Lung Cancer 2019 Jan 4. Epub 2019 Jan 4.

UC Davis Comprehensive Cancer Center, Sacramento, CA.

Background: Afatinib is a selective, irreversible ErbB family blocker that has shown survival benefit in lung squamous-cell carcinoma (SCC) patients. Pembrolizumab, a humanized immunoglobulin G4 monoclonal antibody to the programmed cell death 1 (PD-1) receptor, has also shown survival benefit in lung SCC. Concurrent inhibition of the PD-1 and epidermal growth factor receptor (EGFR) pathways represents a rational approach to improve responses and delay the onset of treatment resistance in lung SCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.022DOI Listing
January 2019
1 Read

Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System.

Clin Lung Cancer 2018 Dec 22. Epub 2018 Dec 22.

Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.

Introduction: Financial distress has been established as a clinically relevant patient-reported outcome associated with worse mortality and quality of life. Our goal was to define factors associated with financial burden (FB) in a public health care system.

Materials And Methods: Patients with advanced lung cancer were recruited from outpatient clinics at the Princess Margaret Cancer Centre (Toronto, Canada). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.010DOI Listing
December 2018
1 Read

Increased Galectin-1 Expression in Thymic Epithelial Tumors.

Clin Lung Cancer 2018 Dec 21. Epub 2018 Dec 21.

Department of Radiation Oncology, Stanford University School of Medicine Stanford Cancer Institute, Stanford, CA.

Introduction: Thymic epithelial tumors (TET) are rare malignancies with a paucity of data on biology and therapeutics. Galectin-1 is a member of the β-galactoside binding protein family and has been shown to mediate tumor growth via modulation of immune cell function. This study examined galectin-1 expression in TET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.005DOI Listing
December 2018

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.

Background: KRAS and TP53 are common mutations in non-small-cell lung cancer (NSCLC). The Lung Adjuvant Cisplatin Evaluation Biological Program group found adjuvant chemotherapy to be deleterious in patients with coexisting KRAS/TP53 mutations.

Patients And Methods: To validate these results, patients with NSCLC tested for KRAS and TP53 mutations and receiving chemotherapy for any stage NSCLC were selected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.009DOI Listing
December 2018
3 Reads

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

St Luke's International Hospital, Tokyo, Japan.

Background: Cabozantinib inhibits tyrosine kinases including MET, AXL, VEGFR2, RET, KIT, and ROS1 and has demonstrated antitumor activity in multiple tumor types. The primary objective of this phase 1 study (NCT01553656) was to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of cabozantinib in Japanese patients.

Patients And Methods: Patients with advanced solid tumors were enrolled at 2 sites in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.018DOI Listing
December 2018
8 Reads

Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.

Clin Lung Cancer 2018 Dec 29. Epub 2018 Dec 29.

Department of Radiation Oncology, Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN. Electronic address:

Introduction/background: Many patients with early stage non-small-cell lung cancer (ES-NSCLC) undergoing stereotactic body radiation therapy (SBRT) develop metastases, which is associated with poor outcomes. We sought to identify factors predictive of metastases after lung SBRT and created a risk stratification tool.

Materials And Methods: We included 363 patients with ES-NSCLC who received SBRT; the median follow-up was 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.016DOI Listing
December 2018
2 Reads

Immunotherapy for LELC: Case Report and a Focused Review.

Clin Lung Cancer 2018 Dec 21. Epub 2018 Dec 21.

Oncologie Médicale, Hôpitaux Universitaires Paris Seine-Saint-Denis, Hôpital Avicenne, Bobigny Laboratoire d'Oncoim, Oncology, Bobigny, France. Electronic address:

Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare, Epstein-Barr virus-associated tumor. LELC occurs mostly in young, Asian nonsmokers. A few hundred cases have been reported, mostly from retrospective Asian studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.008DOI Listing
December 2018
2 Reads

Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.017DOI Listing
December 2018

Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

Department of Radiology, Samsung Medical Center, Seoul, Korea; Sungkyunkwan University School of Medicine, Seoul, Korea.

Purpose: To determine the outcomes of transthoracic rebiopsy for epidermal growth factor receptor (EGFR) mutation in patients with lung adenocarcinoma and to explore the clinical and procedure-related risk factors for the acquisition of nondiagnostic rebiopsy specimens.

Patients And Methods: We retrospectively reviewed 367 patients with lung adenocarcinoma who underwent transthoracic core needle biopsy for mutation analysis from September 2011 to October 2016. Of these, 199 patients underwent rebiopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.021DOI Listing
December 2018
2 Reads

Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.

Clin Lung Cancer 2019 Jan 2. Epub 2019 Jan 2.

University of Colorado Cancer Center, Aurora, CO.

The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving atezolizumab. These results changed the standard first-line therapy for the first time in several decades. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.019DOI Listing
January 2019

Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 Nov 29. Epub 2018 Nov 29.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Introduction: Platinum doublet chemotherapy has represented the standard of care in advanced non-small-cell lung cancer for decades. Targeting platelet-derived growth factor receptors (PDGFR) is a potential mechanism to improve the efficacy of first-line therapy. This randomized phase 1b/2 trial investigated the addition of the anti-PDGFRα monoclonal antibody MEDI-575 to first-line carboplatin/paclitaxel (CP) chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.012DOI Listing
November 2018
4 Reads

Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-like Carcinoma: Summary of Eighty-five Cases.

Clin Lung Cancer 2018 Dec 24. Epub 2018 Dec 24.

State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of the Respiratory Health, Shunde Affiliated Hospital of Guangzhou Medical University, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Electronic address:

Background: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of lung cancer that is less reported and not well-understood.

Materials And Methods: We investigated the clinical features of 85 patients with PLELC to determine the prognostic factors.

Results: PLELC preferentially affected the young (71. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.014DOI Listing
December 2018
3 Reads

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

Introduction: Non-small-cell lung cancer (NSCLC) patients harboring ALK or ROS1 rearrangements invariably acquire resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs), most notably ALK G1202R and ROS1 G2032R. Lorlatinib, a novel third-generation TKI, produced remarkable results from the first-in-man phase 1 trial: an overall response rate of 46% and 50% for previously treated ALK- and ROS1-positive patients, respectively. However, the efficacy of lorlatinib has not been widely validated in Asian patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183035
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.020DOI Listing
December 2018
7 Reads

Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.

There is a rising need for optimal biomarkers to better tailor treatments for patients with cancer in the era of immunotherapy. In addition to programmed death-ligand 1 (PD-L1) and tumor mutation burden (TMB), neutrophil-to-lymphocyte (NLR) is regaining interest as a biomarker in immunotherapy for its availability, accessibility, and reproducibility. High NLR, according to different thresholds, is consistently reported to correlate with poor prognosis in different treatments in several cancers. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183032
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.003DOI Listing
December 2018
9 Reads

Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France; Service de Pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, GRC-04 Theranoscan, Université Paris VI, 75970 Paris, France.

Introduction: Evaluation of EGFR Mutation status for the administration of EGFR-TKIs in non-small cell lung Carcinoma (ERMETIC) was a prospective study designed to validate the prognostic value of EGFR/KRAS mutations in patients with advanced non-small-cell lung cancer (NSCLC), all receiving a first-generation tyrosine kinase inhibitor, erlotinib. ERMETIC2 was an ancillary project evaluating the clinical value of common EGFR/KRAS-mutated subclones regarding prognosis using highly sensitive molecular detection methods.

Materials And Methods: Tumor samples from 228 patients with NSCLC (59% adenocarcinoma, 37% women, and 19% never/former smokers) were available for reanalysis using alternative highly sensitive molecular techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.012DOI Listing
December 2018
3 Reads

EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.

Clin Lung Cancer 2018 Dec 27. Epub 2018 Dec 27.

Department of Internal Medicine, Division of Hematology/Oncology, UC Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183035
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.015DOI Listing
December 2018
4 Reads

Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma.

Clin Lung Cancer 2018 Dec 24. Epub 2018 Dec 24.

Department of Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.013DOI Listing
December 2018
3 Reads

Role of Skip Mediastinal Lymph Node Metastasis for Patients With Resectable Non-small-cell Lung Cancer: A Propensity Score Matching Analysis.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Background: N2 disease represents a heterogeneous group of non-small-cell lung cancer (NSCLC) with varying 5-year overall survival (OS) rates. The skip N2 phenomenon is quite frequent, and its prognostic impact remains a matter of debate. The aim of this study is to further assess the clinical significance and prognostic value of skip N2 disease using propensity score matching. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183033
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.007DOI Listing
December 2018
8 Reads

Disparities in the Treatment and Outcome of Stage I Non-Small-Cell Lung Cancer in the 21st Century.

Clin Lung Cancer 2018 Nov 20. Epub 2018 Nov 20.

Department of Radiation Oncology, Institute for Academic Medicine, Research Institute, Houston Methodist Hospital, Houston, TX. Electronic address:

Background: African American (AA) individuals are less likely to receive treatment and more likely to die from cancer compared with Caucasian (C) individuals. Recent advancements in surgery and radiation have improved outcomes in early stage non-small-cell lung cancer (ESNSCLC). We studied racial disparities in ESNSCLC in the past decade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.004DOI Listing
November 2018
2 Reads

Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Sichuan, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.004DOI Listing
December 2018
4 Reads

Prognostic Understanding and Quality of Life in Patients With Advanced Lung Cancer: A Multicenter Study.

Clin Lung Cancer 2018 Dec 13. Epub 2018 Dec 13.

Multidisciplinary Oncology Center Antwerp, Antwerp Hospital University, Edegem, Belgium.

Introduction: Communication about the palliative setting remains a barrier for many physicians because they are afraid to harm the patient by giving bad news. We sought to determine whether this a valid concern; the influence of prognostic understanding on patients' quality of life (QoL); and which factors influence this relationship.

Methods: The present multicenter, cross-sectional study used a questionnaire to measure patients' prognostic understanding, QoL, mood, and coping strategy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183030
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.11.011DOI Listing
December 2018
4 Reads

Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Department of Hematology and Oncology, Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.006DOI Listing
December 2018
1 Read

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Unit of Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address:

Advanced lung adenocarcinoma with inactive liver kinase B1 (LKB1) tumor suppressor protein is associated with poor response to immune checkpoint inhibitors and molecularly targeted agents, and with dismal patient prognosis. LKB1 is a central orchestrator of cancer cell metabolism, and halts tumor growth/proliferation during metabolic stress. Recent preclinical evidence suggests that LKB1-inactive lung adenocarcinoma is highly sensitive to metformin, a safe and low-cost antidiabetic compound that inhibits mitochondrial oxidative phosphorylation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.011DOI Listing
December 2018
7 Reads

A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L).

Clin Lung Cancer 2019 Mar 11;20(2):139-141. Epub 2018 Dec 11.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

Immune-checkpoint inhibitors (ICIs) play an important role in treatment for advanced non-small-cell lung cancer. Over one-half of patients, however, have relapse. Although rechallenge treatment of anti-cancer drugs that showed efficacy in prior lines of therapy has been broadly accepted in lung cancer, evidence of efficacy of rechallenge of ICIs has been limited to anecdotal case series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.001DOI Listing
March 2019
2 Reads

Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.

Clin Lung Cancer 2019 Mar 29;20(2):117-123. Epub 2018 Nov 29.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Background: We sought reliable markers of survival and disease control among patients treated for limited-stage small-cell lung cancer (LS-SCLC).

Patients And Methods: Subjects were 122 patients given (chemo)radiotherapy for LS-SCLC at MD Anderson in 2002 through 2015. Pretreatment total lymphocyte count (TLC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were analyzed for associations with overall (OS) and progression-free survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.013DOI Listing
March 2019
3 Reads

MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis.

Clin Lung Cancer 2018 Dec 12. Epub 2018 Dec 12.

Department of Pathology, CHRU Brest, Brest, France; Inserm U1053 BaRITOn, Bordeaux, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183032
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.002DOI Listing
December 2018
9 Reads

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases.

Clin Lung Cancer 2019 Mar 29;20(2):e152-e157. Epub 2018 Nov 29.

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX; Harold C. Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Veterans Affairs, North Texas Health Care System, Dallas, TX. Electronic address:

Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid and PubMed, literature published from 2000 through 2016 was searched using the terms "primary pericardial mesothelioma," "pericardial mesothelioma," and "malignant pericardial mesothelioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.008DOI Listing
March 2019
2 Reads